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Abstract
Marchiafava ‑Bignami disease is a rare condition associated with chronic alcohol consumption and/or malnutrition, 
characterized by demyelination of the corpus callosum, generally attributed to a deficiency in B complex vitamins.
We report the case of a 34 ‑year ‑old male with a 10 ‑year history of alcohol dependence who was admitted to the 
hospital, after having been found lying on the floor of his house, malnourished and with pressure ulcers on his chest 
and knees. On clinical observation he was found to be alert but mute. He followed some simple orders. Generalized 
spastic hypertonia was present. Magnetic resonance imaging showed demyelination of the corpus callosum, suggesting 
the diagnosis of Marchiafava ‑Bignami disease. He was admitted to the Psychiatry Inpatient Unit and evaluated by a 
multidisciplinary team. He received thiamine, corticosteroids and rehabilitation. After a week, his speech was slurred 
but comprehensible and he could walk with aid; magnetic resonance imaging findings had improved. After three months 
in a Convalescence Unit, he was discharged with total autonomy. 
Resumo
A doença de Marchiafava ‑Bignami é uma condição rara associada ao consumo crónico e abusivo de álcool e/ou 
desnutrição, caracterizada por desmielinização do corpo caloso, sendo geralmente atribuída a uma deficiência de 
vitaminas do complexo B.
Apresentamos o caso de um homem de 34 anos com 10 anos de dependência de álcool que foi trazido ao hospital, 
após ter sido encontrado caído no chão de sua casa em decúbito ventral, desnutrido, com úlceras de pressão no tórax 
e joelhos. Estava vígil, não emitia discurso, cumpria ordens simples e apresentava hipertonia espástica generalizada. 
Na ressonância magnética identificou ‑se desmielinização do corpo caloso, sendo diagnosticado com doença de 
Marchiafava ‑Bignami. Foi internado no serviço de psiquiatria e avaliado por uma equipa multidisciplinar, iniciando 
terapêutica com tiamina e corticosteróides e um programa de reabilitação. Após uma semana, apresentava melhoria 
clínica e imagiológica. Após um período de 3 meses numa Unidade de Convalescença, teve alta totalmente autónomo.
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INTRODUCTION
Marchiafava ‑Bignami disease (MBD) is a rare condition 
associated with chronic alcohol consumption and/or mal‑
nutrition, characterized by demyelination and necrosis of 
the corpus callosum that is thought to be attributed to a 
deficiency in the B complex vitamins.1
CASE REPORT
A 34 ‑year ‑old male was brought to the emergency room, 
after having been found lying on the floor of his house, 
where he lived alone. He was malnourished and had pres‑
sure ulcers on his chest and knees. He was alert, with no 
spontaneous speech. He was able to follow some simple 
orders and presented generalized spastic hypertonia.
He had a 10 ‑year history of alcohol dependence, with a 
current daily intake of 5 L of wine. He denied other sub‑
stance use. No previous psychiatric, neurologic or medical 
conditions were known. He had no clinically relevant 
family history. He did not consult his family physician 
regularly nor was he on any medication. 
A computed tomography ‑scan revealed brain atrophy. 
Laboratory blood testing revealed increased mean red cell 
corpuscular volume and leukocytosis, elevated gamma 
glutamyl transpeptidase and creatine kinase levels, hy‑
pokalemia and folate deficiency. After observation by a 
Psychiatrist and with a working hypothesis of a diagnosis 
of Wernicke’s encephalopathy, the patient was admitted to 
the Internal Medicine Department and started on vitamin 
B complex therapy (parenteral thiamine 1500 mg and oral 
folic acid 5 mg daily) and diazepam.
A magnetic resonance imaging (MRI) of the brain per‑
formed two days later, showed diffuse demyelination of 
the corpus callosum and multifocal demyelination of the 
superficial and subcortical semi ‑oval centers of the high 
and medium frontal convexities with a slight anterior pa‑
rietal extension, in keeping with the diagnosis of MBD in 
acute phase. (Fig. 1) 
Figure.1  ‑ Diffuse hyperintensity of the corpus callosum on T2/FLAIR  ‑ “sandwich sign”
An electroencephalogram showed moderately slow (6 Hz) 
electrogenicity without asymmetries or paroxysmal activi‑
ty, possibly in the context of a metabolic encephalopathic 
dysfunction. After a consultation with a Neurologist, he 
received corticosteroids (parenteral methylprednisolone 
1000 mg daily) for three days. Thiamine was then reduced 
to 600 mg daily for 5 days, after which he remained on a 
200 mg daily oral dose. 
The patient remained in the Internal Medicine Department 
for one week, for hydration and correction of hydroelectro‑
lytic disorders, after which he was transferred to the Psy‑
chiatry ward. On admission, he was alert, partially oriented 
to place and time, with focused and sustained attention. 
His speech was slow and poor (with moderate dysarthria 
and hypophonia). His mood was neutral with flattening 
of affect. His thought process appeared to be organized 
but he had behaviour suggestive of illusions or hallucina‑
tions. Despite showing psychomotor delay, he could now 
move himself on the bed and take small steps with aid. A 
brief neuropsychological evaluation was performed that 
additionally showed ideomotor and ideational apraxia, 
perceptive alterations (suggesting alteration of the body 
scheme) and marked changes in executive functioning.
By indication of the Physical Medicine and Rehabilitation 
Department, the patient started a program of physiotherapy 
and occupational therapy, as well as antispasmodic therapy. 
The Dietary and Nutrition Service initiated a personalized 
diet. The Social Service was contacted to arrange a future 
referencing to a Convalescence Unit.
A control MRI, performed two weeks after admission, re‑
vealed decreased thickness of the corpus callosum, report‑
ed as being due to a diffuse decrease of brain parenchyma 
or as consequence of the diffuse demyelination previously 
detected, alterations consistent with MBD in subacute 
phase. (Fig. 2)
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Figure. 2  ‑ Small hyperintense T2/FLAIR foci in the splenius of the corpus callosum
Two weeks after the brief neuropsychological evaluation 
the patient underwent a comprehensive one, which de‑
scribed changes in speech (poor, hypophonic and moder‑
ate dysarthria), difficulties in maintaining memory after 
interference, deficits in various areas such as sustained 
attention, immediate retention, logical reasoning, concep‑
tual organization, the ability to criticize absurd situations, 
verbal initiative, mental flexibility, and the ability to resist 
interference, along with apraxia (ideomotor and idea‑
tional), perceptual alterations and slow processing speed 
(mental and motor). Compared to the previous evaluation 
there was a favorable cognitive evolution. Nevertheless, 
the overall picture suggested a strong impairment in exec‑
utive domains.
The patient was then admitted to a Convalescence Unit, 
medicated with a daily oral dose of 200 mg thiamine. Af‑
ter 3 months he was discharged with total autonomy for 
the activities of daily living, referenced to an addiction 
recovery center. Unfortunately, he suffered a relapse of his 
alcohol consumption.
DISCUSSION
MBD is a rare condition characterized by demyelination 
and necrosis of the corpus callosum.1 First reported in 1903 
in Italian alcoholics,2 it is associated with patients who have 
a history of chronic alcohol ingestion; however, it has also 
been reported in diabetic and malnourished non ‑alcoholic 
patients.3 ‑5 It mainly affects the male population, in the age 
group between 40 and 60 years. The actual pathogenesis of 
the disease remains uncertain, but it is thought to be attrib‑
uted to a deficiency in the B complex vitamins.6
There is no standard clinical picture in MBD and the pos‑
sible initial manifestations are non ‑specific of the condi‑
tion.7 According to the clinical classification of Brion et al, 
MBD may present in an acute form, with impairment of 
consciousness, seizures, and rapid death; a subacute form, 
with variable degrees of mental confusion, dysarthria, be‑
havioral abnormalities, memory deficits and impairment 
of gait; and a chronic form, characterized by progressive 
dementia, behavioral abnormalities and signs of interhem‑
ispheric disconnection. If diagnosis and treatment are not 
timely, MBD may progress to coma or even death.6,8,9
With advances in neuroimaging techniques, early diagno‑
sis of MBD has become possible on the basis of clinical 
findings in combination with radiological imaging fea‑
tures demonstrated by computed tomography (CT) and/or 
MRI.10,11
On CT, the corpus callosum is hypodense, except in cas‑
es characterized by subacute hemorrhage, in which the 
lesions may be isodense or hyperdense. Because CT has 
a lower sensitivity than MRI, it may show no alterations 
when the lesions are small.9,11
On MRI, the typical changes seen in acute MBD include 
symmetric T2W ‑hyperintense and T1W ‑hypointense le‑
sions of the central part of the body of the corpus callosum 
(with relative sparing of thin upper and lower edges – this 
being known as the “sandwich sign”). After the acute 
stage, the T2 ‑signal of the corpus callosum (related with 
edema), normalizes and, later on, symmetric atrophy of the 
corpus callosum with focal hypointensities on T1WI with 
corresponding focal hyperintensities on T2WI (consistent 
with progressive demyelination, regional necrosis, and 
cyst formations), develop.1,12 Lesions may also be found 
in other regions of the brain, such as the cerebral lobes, 
the hemispheric white matter, and the basal ganglia; such 
extracallosal lesions are found primarily in patients with a 
poor prognosis and severe cognitive impairment.13 ‑16 Our 
patient had the classical “sandwich sign” involving the 
corpus callosum (Fig. 1) and also extracallosal lesions. Ac‑
cording to Wang et al, it is likely that gadolinium enhance‑
ment during acute stage of MBD indicates severe damage 
and may lead to necrosis in the chronic stage, which is 
associated with poorer clinical outcome.17
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According to the more recent clinical ‑radiologic classifica‑
tion by Heinrich et al, there are two subtypes of MBD. Type 
A is characterized by an acutely altered state of conscious‑
ness, cognitive deterioration and language deficits, focal 
neurological deficits, T2 ‑WI hyperintense swelling of the 
entire corpus callosum, frequently with extracallosal lesions 
and a poor prognosis. Type B evolves with insidious clini‑
cal onset and progression, less severe and disabling clinical 
symptoms and less long ‑term disabilities; T2 ‑WI hyperin‑
tense lesions only partially involve the corpus callosum with 
extracallosal lesions being less frequently seen, and a better 
outcome.18 Considering our patient’s clinical ‑radiologic pic‑
ture, he should be categorized into type A, but his clinical 
progression was not as poor as would be expected.
The treatment of MBD is still controversial. Assuming 
the implication of nutritional factors in its pathogenesis, 
in a way similar to Wernicke´s encephalopathy, it is sug‑
gested that vitamin B complex replenishment should be 
instituted, with parenteral administration of thiamine be‑
ing carried out until behavioral symptoms are reversed.6 
There are variable reports of doses used (between 75 and 
1000 mg/kg) and duration of treatment (between 1 and 12 
weeks) until clinical improvement.5,6,10,13,20 ‑22
Some authors also propose the co ‑administration of cor‑
ticosteroids in the acute phase to reduce cerebral edema, 
suppress demyelination, stabilize of the blood ‑brain barri‑
er and reduce inflammation, contributing to improvement 
of clinical response.4,5,6,23,24 This is controversial because 
most cases were treated with thiamine and corticosteroids 
concomitantly and it was difficult to assess which of the 
two had the preponderant role in recovery.10 We made the 
clinical decision to follow both strategies in our case with 
partial clinical and radiological recovery.
Concerning the prognosis of MBD, it tends to be worse in 
alcoholic patients, but can be improved if promptly diagnosed 
and expeditiously treated.25 According to an analysis of 153 
cases by Hillbom et al, early initiation (within two weeks af‑
ter the onset of the clinical picture) of thiamine replacement 
improves MBD prognosis and represents the only limiting 
factor in patient outcome.10 More recently, the results of an 
observational study by Dong et al, established some factors 
of poor prognosis in patients with an acute or subacute onset: 
having heavy alcoholic habits, extracallosal lesions, cerebral 
lobe impairment and severe disturbances of consciousness.7
CONCLUSION
Considering the initial clinical ‑radiologic picture, we con‑
sider that a prompt diagnosis and initiation of treatment 
(with thiamine and high ‑dose corticosteroids) by a dedi‑
cated multidisciplinary team resulted in a better than ex‑
pected improvement for our patient. We hypothesize that 
the patient’s young age and the absence of comorbidities 
also contributed to this favorable outcome.
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